Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDNF Parkinson's race: Amgen plans Phase I with Medtronic device; Genentech licenses neurturin.

Executive Summary

AMGEN GDNF PHASE I TRIALS WILL EXAMINE INTRAVENTRICULAR DOSING as well as standard analysis of safety and tolerability of glial-derived neurotrophic factor. The early-stage Parkinson's disease drug is nearing the start of human trials, and Phase I studies in patients with modest to moderately severe Parkinson's are projected to begin later this year, the company told the financial community at a March 25 meeting in New York City.
UsernamePublicRestriction

Register

PS027951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel